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ABSTRACT

The ECM of epithelial carcinomas undergoes structural remodeling during
periods of uncontrolled growth, creating regional heterogeneity and torsional stress.
How tumors maintain ECM integrity in the face of dynamic biophysical forces is still
largely unclear. This study addresses these deficiencies using mouse models of
human lung adenocarcinoma. Spontaneous lung tumors were marked by
disorganized basement membranes, dense collagen networks, and increased tissue
stiffness. Metastasis-prone lung adenocarcinoma cells secreted fibulin-2 (Fbln2), a
matrix glycoprotein involved in ECM supra-molecular assembly. Fibulin-2 depletion
in tumor cells decreased the intra-tumoral abundance of matrix metalloproteinases
and reduced collagen cross-linking and tumor compressive properties resulting in
inhibited tumor growth and metastasis. Fbln2 deposition within intra-tumoral fibrotic
bands was a predictor of poor clinical outcome in patients. Collectively, these
findings support a feed-forward model in which tumor cells secrete matrix-stabilizing
factors required for the assembly of ECM that preferentially favors malignant
progression. To our knowledge, this is the first evidence that tumor cells directly
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regulate the integrity of their surrounding matrix through the secretion of matrixstabilizing factors such as fibulin-2. These findings open a new avenue of research
into matrix assembly molecules as potential therapeutic targets in cancer patients.
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CHAPTER 1
__________________________________________________________________

INTRODUCTION

Epithelial tumors contain an extracellular matrix (ECM) with biophysical and
biochemical features that differ sharply from those of adjacent normal tissue stroma
(1). Tumor ECM is composed of a diverse array of proteins intricately oriented
within a three-dimensional scaffold. These proteins include collagen fibers that
serve as a structural backbone for attached glycoproteins, sulfated proteoglycans,
and loosely-tethered peptide ligands (1). In response to environmental stimuli, cells
secrete intrinsic matrix molecules, which integrate into and modify the surrounding
scaffold through the actions of matrix cross-linking enzymes, assembly-stabilizing
proteins, and proteases (2). Lysyl oxidase induces a critical step in matrix
maturation through collagen cross-linking, which enhances matrix rigidity (3). Once
thought to be simply a function of collagen cross-linking, tissue biomechanical
properties are also modified by the deposition of proteoglycans and other ECM
proteins (4). How collagen contributes to the development and progression of
cancer is unclear, but malignant transformation is accompanied by dramatic
increases in ECM stiffness, elevated compression forces, and high tensional
resistance stresses (5). The presence of collagen-dense fibrotic foci within
mammary carcinomas is correlated with adverse prognosis, and increased
expression of collagen type I is associated with increased risk of metastasis in
1

breast, lung, and prostate cancers (6). Moreover, tumor cells migrate and invade
following adherence to RGD sequences on mature matrix surfaces through integrin
receptors, which are linked to an intracellular network of actin cytoskeletal and cell
cortex proteins (3, 7).
Intra-tumoral matrix proteins originate from a variety of cell types, including
cancer-associated fibroblasts (CAFs). In KrasLA1 mice, which develop nonmetastatic lung adenocarcinomas owing to expression of a latent, somatically
activated KrasG12D allele (8), CAFs isolated on the basis of Thy-1 (CD90) expression
exhibit sharp differences from Thy-1pos normal lung fibroblasts (LFs), including
morphological and biochemical features of myofibroblasts, higher secretion of
diverse cytokines and chemokines, and more potent pro-invasive effects on tumor
cells (9). CAFs are thought to be largely responsible for the desmoplastic response
observed in epithelial tumors characterized by a pronounced deposition of
collagens, fibronectin, proteoglycans, and glycosaminoglycans (10). Another source
of intrinsic matrix molecules is the tumor cell itself, and initial evidence suggests that
the matrix molecules originating from tumor cells are critical for malignant
progression. For example, breast cancer cells express tenascin C, which binds to
membrane receptors on tumor cells that enhance the expression of stem cell factors
that support metastasis-initiating ability (11). Thus, tumor cells direct matrix
composition and function through secretion of key matrix molecules and recruitment
of CAFs, but the matrix molecules that dictate tumor fate have not been fully
defined.
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To identify ECM molecules secreted by tumor cells that promote metastasis,
proteomic profiling studies have been carried out on syngeneic tumor cell lines with
low or high metastatic potential derived from lung adenocarcinomas which develop
in mice that co-express the latent KrasG12D allele and a Trp53R172HG allele
(designated “KP” cells and mice) (12). Numerous ECM proteins were differentially
expressed, including intrinsic matrix proteins, matrix cross-linking enzymes, cell
adhesion molecules, peptidases, and peptidase inhibitors (13). Of particular
interest, fibulin-2 was 7.16-fold more abundant in the conditioned media of
metastatic KP cells. A matrix glycoprotein and one of seven genes in the fibulin
family, fibulin-2 is abundant in elastic and fibrous tissues within vessel walls and
other structures (14). In cancer cells, fibulin-2 expression is quite variable, and
forced expression of exogenous fibulin-2 is oncogenic or tumor suppressive in
different cell types (15, 16). Although its physiological role is not clear, fibulin-2 is
thought to stabilize the assembly of a variety of macromolecular structures,
including tropo-elastin fibers, microfibrils, and matrix-proteoglycan complexes (17,
18). Supporting its matrix-stabilizing capacity, fibulin-2 has a carboxy-terminal
globular domain and a tandem array of calcium-binding epidermal growth factor-like
modules (19) and forms homodimers that fold into 3- or 4-armed structures (20).
Although Fbln2-null mice have a normal lifespan and display no obvious defects in
ECM ultrastructural features under basal conditions, myocardial infarction in Fbln2null mice induces a clear phenotype of reduced cardiac tissue remodeling,
attenuated TGF-β signaling within damaged cardiac tissues, and significantly
improved survival (21). Collectively, these findings provide a compelling rationale to
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investigate whether fibulin-2 plays a role in the development and remodeling of
tumor ECM.
In this study, we sought to identify factors secreted by tumor cells that
maintain ECM integrity in the face of dynamic biophysical forces that create regional
heterogeneity and torsional stress. We found that KrasLA1 mice and syngeneic wildtype mice injected orthotopically or subcutaneously with metastatic KP cells
developed desmoplastic tumors with disorganized basement membranes owing to
infiltration by collagen-secreting CAFs. KP cells secreted abundant fibulin-2, and
fibulin-2 depletion disrupted the integrity of tumor ECM and inhibited tumor growth
and metastasis. On the basis of findings reported here, we propose a feed-forward
model in which tumor cells secrete matrix-stabilizing factors required for the
assembly of an ECM that favors malignant progression.
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__________________________________________________________________
CHAPTER 2
__________________________________________________________________

METHODS

Animal husbandry and syngeneic tumor cell injections
Before their initiation, all mouse experiments were submitted to and
approved by the Institutional Animal Care and Use Committee at the University of
Texas M.D. Anderson Cancer Center. KrasLA1/+ and KrasLA1/+ p53R172H∆g/+ double
mutant mice received standards of care and were euthanized according to the
standards set forth by the IACUC. As previously described (22), subcutaneous
tumors were generated in 129S2/SvPasCrlf mice matched on the basis of age (2 to
4 months) and gender by injection with syngeneic tumor cells (106) subcutaneously
into the right flank in 100 µl phosphate-buffered saline (PBS). Mice were monitored
daily for 6 weeks, at which time necropsies were performed to isolate and weigh the
primary tumors and count lung metastases. Intra-thoracic (orthotopic) injections
were performed as previously described (23). Briefly, 129/SV syngeneic mice
matched on the basis of age (2 to 4 months) and gender were injected in the left
lung lobe with 20,000 cells suspended in 50 µl of 1:10 diluted growth-factor reduced
matrigel in Hank’s balanced salt solution (BD Biosciences, San Jose, CA). Mice
were monitored daily for 2 weeks, at which time necropsies were performed to
isolate and weigh the lung tissue and assess lymph node metastasis.
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Creation of lung scaffolds and their use in an ex vivo perfusion model
Age-matched adult rat or mouse lungs were de-cellularized using methods
previously described (24). Briefly, lung tissue was harvested and native cells were
removed using 1% sodium dodecyl sulfate and 1% Triton X-100 diluted in H20 in a
de-cellularization chamber. Murine lung scaffolds were studied immediately or snap
frozen for LC-MS/MS analysis, and rat scaffolds were used immediately for recellularization experiments in the ex vivo lung perfusion model. Briefly, 344SQ cells
(2.5 x 107) were seeded through the rat lung trachea in a customized bioreactor with
perfusion of oxygenated media through the pulmonary artery for 7 to 14 days (24)
as described, at which point conditioned media were collected and lung lobes were
formalin-fixed.

Micro-CT of devitalized lung tissue
Devitalized normal or tumor burdened lungs were devitalized as previously
described (24). The trachea was cannulated with a 20 gauge catheter and tied into
place with a thread. Lungs (n=3, each group) were inflated with 0.5 ml of bariumsulfate contrast agent followed by micro-CT scans on a Phystech Novis small
animal imaging instrument and analysis using GE Healthcare MicroView 3D Image
Viewer & Analysis Tool (http://microview.sourceforge.net/).

Mechanical Testing
For analysis of tissue compressive properties, lung disks of equal diameter
were isolated by punch biopsy. Sample dimensions were measured using digital
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calipers prior to compression testing (n = 4 per formulation). Compressive testing
was performed using an Instron Model 3340 mounted with a 10 N load cell. Instron
Series IX/s software was used for testing control, and data acquisition as uniaxial
compressive strain was applied at 0.2 mm min-1.

Force-elongation data was

converted to stress-strain data with corrected cross-sectional area and plotted to
derive the elastic modulus from the slope of the linear portion of the curve.

Fractionation and LC MS/MS mass spectrometry
De-cellularized lung matrices from wild-type and KrasLA1 mutant mice (4 of
each type) and fibroblast matrices from LFs and CAFs (3 of each type) were
prepared as described above. Following de-cellularization, the lung and fibroblast
matrices were flash frozen in liquid nitrogen and stored at −80°C until subsequent
processing for protein. For LC/MS-MS analysis, tumors were homogenized on liquid
nitrogen and protein extracted as previously described (25). In brief, samples were
lysed first in a modified RIPA buffer (PBS, pH7.4; 0.1% SDS; 0.25% Nadeoxycholate) with phosphatase and protease inhibitors at 2 ml/g, followed by
further extraction of the insoluble fraction with a urea lysis buffer (PBS, pH7.4; 5.0M
urea, 2.0M thiourea; 0.1% SDS; 50mM DTT).

SDS and Na-deoxycholate was

removed from the samples prior to fractionation with detergent removal spin
columns (Pierce). Lung scaffold lysates were reciprocally labeled with either
acrylamide (Fluka) or

13
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C-

C-acrylamide (Cambridge Isotope Laboratories), combined

and reduced overnight in DTT prior tofractionation on a POROS R1 10 mM column
(4.6x 100mm, Applied Biosystems).

Fibroblast matrix lysates were reduced
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overnight in DTT prior to fractionation. Individual fractions for both sample types
were trypsin digested and combined into 24 pools. Pools were then analyzed in a
LTQ-ORBITRAP

mass

spectrometer

(Thermo-Finnigan)

with

a

nanoflow

chromatrography system (Eksigent).Acquired mass spectrometry data were
automatically processed by the Computational Proteomics Analysis System (CPAS)
pipeline using the X!Tandem search algorithm configured with the K-score module
plug-in. The tandem mass spectra were searched against a mouse IPI database
(v3.64) (lung scaffolds) or a composite database of IPI mouse (v3.64) and IPI
bovine (v3.50) (fibroblast matrices). To estimate the significance of peptide and
protein matches, we applied the tools of PeptideProphet and ProteinProphet.
Peptides identified with PeptideProphet probability of a minimum 0.05 were selected
and submitted to ProteinProphet; for fibroblast matrix lysates, peptides with shared
bovine sequence were not included. The derived protein identifications were filtered
at a maximum 5% error rate. Peptide quantitation was computed by the Q3
quantitation tool using peptides achieving PeptideProphet probability of a minimum
0.5 and fractional delta mass not exceeding 20 ppm. Enrichment analysis for Gene
Ontology terms was conducted on the differentially expressed proteins by Database
for Annotation, Visualization, and Integrated Discovery (DAVID;(26). GO categories
with p-values >.001 and containing five or fewer genes from the list were discarded.
The protein interacting networks were generated through the use of Ingenuity
Pathway Analysis (IPA; Ingenuity Systems). GO terms represented in the genes
from the clusters of interest were identified using DAVID.
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Flow cytometric isolation of primary lung fibroblasts
CAFs and LFs were isolated from the lungs of KrasLA1 mice and wild-type
littermates, respectively, by flow cytometric analysis to first remove hematopoietic
cells (anti-CD45), endothelial cells (anti-CD31), and epithelial cells (anti-Epcam)
and then positively select fibroblasts using an antibody against cell-surface
glycoprotein Thy-1 (CD90) (Fig. 3A-C), which is expressed on subsets of normal
lung fibroblasts and lung cancer-derived CAFs (27). Briefly, murine lungs were
digested into single cell suspension by immersion in 3 mg/mL of collagenase type I
(Worthington, Lakewood, NJ) and 4 mg/mL dispase II (Roche, Indianapolis, IN) and
mechanical mincing on a gentleMACS Dissociator (Miltenyi Biotec, Auburn, CA)
followed by gentle rocking at 37°C for 45 minutes. Dispersed cells were centrifuged,
washed with PBS-2% fetal bovine serum (FBS), and subjected to red blood cell
lysis (BioLegend, San Diego, CA). The remaining cells were centrifuged, washed,
filtered (70 and 40 μm) and counted (Countess, Invitrogen, Grand Island, NY) for
further processing. Fibroblasts were isolated by flow cytometry using directly
conjugated monoclonal rat anti-mouse antibodies against CD31, CD45, Ep-CAM,
and Thy-1 and relevant isotype controls tagged with fluorochromes including FITC,
PE, PE-Cy7, or APC purchased from either BD Biosciences, eBioscience (San
Diego, CA), or Biolegend. 7-aminoactinomycin D (7-AAD; 2 μg/mL, Sigma, St Louis,
MO) was used as a viability dye for flow cytometric detection and exclusion of nonviable cells. Cells (5 x 107 cells/mL) were resuspended in PBS and 2% FBS in an
optimally pre-titered cocktail of antibodies and incubated for 45 minutes on ice. The
labeled cells were washed in excess PBS-2% FBS and resuspended at 5-10 x 106
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cells/mL and held on ice for flow cytometric analysis and sorting using a FACSAria
cell sorter (BD Biosciences). Fibroblasts were cultured in -modified essential
medium

(MEM)

(Cellgro,

Corning,

NY)

supplemented

with

20%

FBS,

penicillin/streptomycin, L-glutamine, and sodium pyruvate. Primary cells used in
experiments had been passaged fewer than 6 times.

Sphere assays
Lab-Teck II eight chamber-well sterile slides were coated with Growth FactorReduced Matrigel (BD Biosciences). GFP-expressing 344SQ cells were seeded
(900 cells per well) and cultured for 10 days or more in RPMI1640 containing 10%
FBS + 0.2 % Matrigel to form spheres on the surface of the Matrigel. Fibroblasts
(300 per well) were seeded on top of the established spheres, and the co-cultures
were photographed at 10x after 72 hr.

Real-time quantitative PCR and ECM-specific PCR array
RNA was isolated from cells using Trizol Reagent (Invitrogen), and 2 μg of
each RNA sample was reverse-transcribed using qSCRIPT (Quanta Biosciences,
Gaithersburg, MD). RT-PCR analysis was performed using the ABI 7500 Fast RealTime PCR System (Applied Biosystems) using the comparative threshold method
with L32 ribosomal protein mRNA as an endogenous reference housekeeping gene.
For each reaction, a standard curve was performed using serial dilutions of a
mixture of cDNA samples. SYBR green I (Applied Biosystems, Foster City, CA) was
used as the fluorophore. All experiments were performed in triplicate. The primer
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sequences used are listed in Table 1. The RT2 Profiler PCR Array, Mouse
Extracellular Matrix & Adhesion Molecules (PAMM-013Z), was performed according
to manufacturer’s instructions (SABiosciences) using 1 g of reverse transcribed
RNA per 96-well plate with SYBR green I fluorophore detection on the ABI PCR
System. Data analysis was performed using SABiosciences RT2 Profiler PCR Array
Data

Software

version

(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php).
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3.5

Table 1. Real-time RT-PCR primer sequences.

Name

Sequence 5'-3'

m-L32 FWD
m-L32 REV
m-Fbln2 FWD
m-Fbln2 REV
m-LOXL3 FWD
m-LOXL3 REV
m-LOXL4 FWD
m-LOXL4 REV
m-MMP-2 FWD
m-MMP-2-REV
m-MMP-7 FWD
m-MMP-7 REV
m-MMP-9 FWD
m-MMP-9 REV
m-Fn1 FWD
m-Fn1 REV
m-Col4a1 FWD
m-Col4a1 REV
m-Lama2 FWD
m-Lama2 REV
m-Lama5 FWD
m-Lama5 REV
m-Lamb1 FWD
m-Lamb1 REV
m-Lamb2 FWD
m-Lamb2 REV
m-Lamc1 FWD
m-Lamc1 REV
m-Lamc2 FWD
m-Lamc2 REV
m-HSPG2 FWD
m-HSPG2 REV

AACAGGGTGCGGAGAAGGT
TGCTCCCATAACCGATGTTG
CGCAGCTCAACACAGAGCACCG
CTGTGCAATCCTGCCACGGGAC
GGAACAGTCTGTGACCGAAAGTG
CACTCAAGTGGATGGCACCCAT
TTCTCGGCTGGCGTTGCTTGTA
GGACTTGGAGAGGCAGTTTTCC
TGGGGGAGATTCTCACTTTG
ACTTGTCCTTCTCCCAGGGT
GAGTGCCAGATGTTGCAGAA
CTGGAATGCCATTTTGGACT
CCAGACGTGGGTCGATTCC
ATGATGGTCCCACTTGAGGC
GACCGGGGACTCACATCCA
AGATTGATAGGGAACTCGTCCA
TATTGAGTCACCTCTCGTGAACA
TGGCTGTCTTAGGCTAATGGG
GTATGGTCTTGAAAATACAACT
GATTCTGCTCTGGAGTTGGTCC
CACCGAAGTGGTCTATTCTGGC
CCTACGCTTACATTGACACTCC
GTACATTGGCTCCAGATGTGATGACT
GGCAATGGTCCCCTTCTGTGTGGT
AGAAGGCAGAGACAGTCCAAGC
GTATTGGTCACCTACTTGTTCC
GTGTGAACGATAACAAGACAGC
CATACCGTTCACCTCATTATCC
TCGTATCAGCACAGTCTCCG
GCAACCTTCTGGCTAATAGAGG
GGAGAGTCCTCCATATGCCA
GGATGGAAGTGTCAGGGAGA
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Cell adhesion assay
Cells were harvested through trypsinization and resuspended as triplicates in
serum containing medium at 5 x 104 cells/ml into a 24-well plate. Plates were
incubated at 37°C for 1, 2, and 3 hour time points. The wells were washed with PBS
to remove non-adhering cells and remaining cells were fixed and stained with 0.1%
crystal violet. The crystal violet dye was solubilized with 10% acetic acid and
transferred into 96-well plates to measure optical density at 595 nm. Cell adhesion
on different ECM substrates was examined based on a modification of a protocol
(28) in which 96-well plates were pre-coated in triplicate with 5 µg/cm² of
corresponding ECM protein overnight at 4°C. Wells were washed with PBS and
blocked with 0.5% BSA for 1 hour at room temp. Cells were serum-starved for 1
hour prior to attachment assay at which point they were trypsinized and
resuspended in serum free media at 5 x 104 cells/mL. Cell suspensions (100 µl)
were added to each well. Cells were allowed to adhere for 1 hour at 37°C followed
by fixation and staining with 0.1% crystal violet, which was solubilized in 10% acetic
acid, and quantified at 595 nm wavelength. Results were expressed as mean
values ± SD from triplicate wells.

Fibroblast matrix isolation
CAF and LF extracellular matrices were isolated based on a modification of
previously published methods (29). Briefly, fibroblast mono-cultures were grown to
confluence in 150 mm plates in α-modified essential medium (Sigma Aldrich)
supplemented with 20% FBS, penicillin/streptomycin, 1X L-glutamine, and 1X
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sodium pyruvate. To enhance matrix secretion, L-ascorbic acid (50 µg/ml) was
freshly prepared and added at each media change. For matrix isolation, cells were
lysed in water for 10 minutes at which point cellular debris was removed. The
remaining matrices (n=3, each group) were scraped from plates and snap frozen for
later mass spec analysis or tumor sphere assays in Matrigel cultures.

Electron microscopy
Transmission electron microscopy (TEM) was performed on glutaraldehydefixed, plastic embedded tissue. The basement membrane along with other ECM
features was assessed at ultrastructural level. Ultrastructural examination allowed
for assessment of the lamina rara and lamina densa of the basement membrane.
The basement membrane was evaluated for intactness, discontinuity, and irregular
architecture, as well as measurement of the thickness of the basement membrane
and its components (lamina rara and lamina densa). In addition, both qualitative and
quantitative assessment of elastic fibers, interstitial collagen fibers, and extracellular
matrix ground substance making up the intertidal compartment were determined.
The ultrastructural characteristics and thickness of the interstitial component of the
samples were assessed both qualitatively and quantitatively. The quantitative
measurements were made using software integrated within the transmission
electron microscope software programs currently available.

Immunofluorescence
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Five µm adult mouse sections were derived as described above. Slides were
rehydrated and incubated in blocking buffer (5% BSA, 1% Skim Milk, 0.05% Triton
X-100 in PBS) for 1 hour at room temperature. Sections were incubated overnight
with antibodies against collagen IV (Abcam) then washed in PBS (0.05% Tween 20)
and incubated with donkey anti-rabbit-FITC (Jackson ImmunoResearch, West
Grove, PA) for 1 hour at room temp and then rinsed. Sections were cover-slipped in
Pro-Long Gold anti-fade mounting media containing DAPI (Sigma Aldrich, St. Louis,
MO). Photomicrographic images were acquired using an Olympus IX71 inverted
fluorescent microscope. Images were colored and overlaid using Olympus DP
Manager software version 2.1.1.163. For chamber slide immunofluorescence, cells
were cultured to confluence on 8 well glass Lab-Tek chamber slides (Thermo
Scientific) and fixed in 1% PFA for 30 minutes followed by blocking with serum-free
protein block (DAKO) for 1 hour. Chamber slides were stained for one hour at room
temperature with polyclonal rabbit antibodies against collagen type I (Abcam),
collagen type IV (Abcam), or laminin (Abcam) and rinsed in PBS (0.05% Tween 20).
Sections were incubated with donkey anti-rabbit Alexa 594 (Invitrogen). Chamber
wells were removed and slides were cover-slipped in Pro-Long Gold anti-fade
mounting media containing DAPI.

Murine lung adenocarcinoma cell lines
All murine adenocarcinoma cell lines used in this study were previously
derived from spontaneously occurring tumors in mice harboring both the K-rasG12D
and p53R172HG/+ genetic mutations (12). Cell lines were named according to the
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mouse number and site of derivation (e.g., 393P, denotes primary lung tumor;
344SQ, subcutaneous metastasis). These cells have alveolar type II cell properties
and variable propensities to undergo EMT and metastasize following injection into
syngeneic mice (22).

Western blot analysis
Lysates from cell lines were harvested using RIPA buffer and were separated
by SDS-PAGE and transferred onto a polyvinylidene fluoride nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA). Membranes were blocked
overnight at 4°C in TBST with 5% nonfat dry milk followed by incubation with
primary antibodies against fibulin-2 (Abcam, Cambridge, MA) and beta actin as an
internal control in TBST with 2.5% nonfat dry milk overnight at 4C. Secondary
antibodies linked to HRP were incubated for 1 hour at room temperature followed by
detection with an enhanced chemiluminescence kit according to the manufacturer's
instructions (Amersham, Pittsburgh, PA). Band intensities were quantified based on
densitometry using Image J Software (http://rsbweb.nih.gov/ij/).

Immunohistochemistry
Mouse and human tissue specimens were fixed in 10% formalin and
embedded in paraffin. Five µm paraffin sections were de-paraffinized with xylene
and rehydrated is ethanol washes followed by incubation in antigen retrieval
solution (DAKO, Carpinteria, CA) for 20 mins at 95°C followed by rinsing and
blocking of endogenous peroxidase with 3% H202 in cold methanol for 20 minutes.
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Slides were rinsed and incubated in blocking buffer (5% BSA, 1% Skim Milk, 0.05%
Triton X-100 in PBS) for 1 hour at room temperature. Sections were then incubated
overnight in a humidified chamber with antibodies against fibulin-2 (Novus
Biologicals) at 1:250 dilution then washed in PBS (0.05% Tween 20) and incubated
with donkey anti-rabbit-HRP (Jackson ImmunoResearch) diluted 1:500 for 1 hour at
room temp and then rinsed and developed 3 to 5 minutes in liquid DAB substrate
solution (DAKO). Slides were rinsed in H20 and counter stained with Meyer’s
hematoxylin, dehydrated, and cover-slipped in xylene-based mounting medium.
Photomicrographic images were acquired using an Olympus IX71 inverted
fluorescent microscope.

Scoring of fibulin-2 expression in human lung cancers.
Immunohistochemical studies were carried out on tumor tissue specimens
obtained from 46 surgically resected human lung adenocarcinomas, stages I-III,
resected with curative intent. All cases were fully annotated for demographic
variables, pathologic stage, smoking status and clinical outcome. Fibrillar and
fibrous fibulin-2 staining was quantified separately in tumor, adjacent normal lung
parenchyma, and lung tissue scars. The distribution of fibulin-2 expression was
quantified in the peripheral areas (defined as the ~25% peripheral portion of the
tumors) and central areas (defined as the ~75% central portion of the tumors).
Scoring was performed by an experienced lung cancer pathologist (I.W.) using the
percentage (0-100%) of the extent of reactivity. For analysis, the pattern of
distribution of tumor scores was characterized (Gaussian, bimodal, etc.). The data
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were analyzed as continuous variables and as dichotomous variables (high versus
low, using median value as a cut point). For each tumor, the final score was the
intensity value multiplied by reactivity extension value (range, 0-300) as previously
reported (30).

Transfection of fibulin-2 short hairpin RNAs (shRNAs)
We

sub-cloned

murine

Fbln2-specific

shRNAs

(Sigma-Aldrich)

and

scrambled shRNA (Addgene, plasmid 1864) into lentiviral pLKO.1 TRC (Addgene,
Plasmid 10878). Additionally, pGIPZ lentiviral vectors containing Fbln2-specific
shRNA sequences (V3LMM_515480 & V2LMM_26531) were purchased (Open
Biosystems, Lafayette, CO). The target sequences for murine fibulin-2 were as
follows:

shFIBULIN-2#1,

GGAGCAGAGGACAATGATA;

shFIBULIN-2#2,

GCACTACCAGCTCAATTTC; shFIBULIN-2#3, CCACTGTGTTCCTCAATTA; and
shFIBULIN-2#4, CGTCTCACTCTACAAGCAA. These vectors were packaged in
293T cells by co-transfection with packaging vectors psPAX2 (Addgene, Plasmid
12260) and pMD2.G (Addgene, Plasmid 12259). Cells (344SQ and 531LN2) were
infected with viral particles and selected in puromycin (10 μg/ml) for up to 14 days
to generate stable transfectants.

Cell proliferation and anchorage independent cell growth
For cell proliferation assay cells were harvested by trypsinization and seeded
at serial dilution concentrations of 1, 10, 100, and 1000 cells in 96-well plates. WST1 assay was carried out at 24, 48, and 72 hours per manufacturer’s instructions
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(Millipore, Billerica, MA) with colorimetric readings taken at 440 nm. Results were
expressed as mean values ± SD from triplicate wells. For anchorage independent
cell growth cells (5 × 104 in 0.3% agar) were seeded onto a layer of 0.8% agar in 6well plates, allowed to proliferate for 21 days, and stained with crystal violet.
Colonies were visualized by light microscopy and scored per field of view. Results
were expressed as mean values ± SD from triplicate wells.

Invasion assays
As described previously (9), cells in serum-free RPMI 1640 (5 × 104) were
seeded onto Transwell plates coated with GFR-Matrigel (BD Biosciences), with
RPMI 1640/10% FBS in the lower well as the chemo-attractant. Each condition was
performed in triplicate or quadruplicate. After 16–18 h of incubation, the medium
was removed and the cells were fixed with 90% ethanol. The migrated cells were
were fixed and stained with 0.1% crystal violet, which was solubilized in 10% acetic
acid, and quantified at 595 nm wavelength. Results were expressed as mean
values ± SD from triplicate wells.

Total and pepsin cleaved collagen content of cells in culture
Hydroxyproline measurements of total collagen were conducted according to
manufacturer’s instructions (Cedar Lane Laboratories, Burlington, NC). Briefly,
equal cell densities were plated and allowed to reach confluence for enhanced
collagen deposition. Cell homogenates were isolated in equal volumes of H20 and
diluted to a final concentration of 6N HCL. Samples were hydrolyzed by baking at
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110°C for 24 hours at which point floating lipid was removed and samples were
evaporated using speed vacuum without heat and resuspend in equal volumes of
H20 for subsequent oxidation with chloramine-T and quantification using DMAB
substrate at 560 nm. Sircol measurements of solubilized collagen were performed
according to manufacturer’s instructions (Biocolor, Carrickfergus, UK) on 4°C
overnight pepsin digested cell extracts (1 mg/mL gastric pepsin) producing
solubilized collagen fragments detected by Picosirius red substrate and acid-salt
wash followed by quantification at 555 nm.

Quantification of stromal collagen density
Tissue sections of fibulin-2-deficient and –replete flank tumors were stained
with Picosirius red according to manufacturer’s instructions (Polysciences,
Warrington, PA). Stained tumor sections were converted into binary images using
Image J software (http://rsbweb.nih.gov/ij/index.html). “Particles” defined as fully
enclosed areas within the binary images were counted in 48 defined areas (grids)
within the interior of the tumor, excluding subcutaneous fascia, and the surface area
of each particle was measured.

Gel zymography
MMP2 and MMP9 enzymatic activities were measured by gelatin
zymography, as previously described by BioRad (Hercules, CA). The gelatin in the
gel was digested by MMP activities and was visualized as a clear band on a
coomassie blue-stained background. Quantitation of the MMP band was performed
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by the Quantity One Gel Documentation System (Bio-Rad Laboratories, Hercules,
CA, USA). Total protein stained with coomassie blue served as a normalization
control.

Statistical Analysis
Numerical values of mouse cohort data were analyzed using student’s t-test
for significance in GraphPad software. The difference was considered significant at
P < 0.05 (two-tailed). Summary statistics for human data were provided to describe
patient characteristics and Fibulin-2 expression. The clinical end points were overall
survival time and time-to-recurrence. Repeated measures analysis using mixed
model was employed to assess the difference in fibulin-2 expression between intratumoral locations. Overall survival duration and time-to-recurrence were estimated
using the Kaplan-Meier method. Comparisons between and among patient
demographic groups were assessed using log-rank test. Univariate Cox proportional
hazard model was applied to assess the effect of covariates and fibulin-2
expression on overall survival time and time-to-recurrence. All computations were
carried out in SAS 9.2 and S-plus 8.0.
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__________________________________________________________________
CHAPTER 3
__________________________________________________________________

RESULTS

A tumor matrix with desmoplastic reaction and infiltration by collagensecreting CAFs
To investigate ECM changes that accompany lung tumorigenesis, lungs from
syngeneic wild-type and KrasLA1 mice were devitalized to generate purified tissue
matrices (termed KrasWT and KrasLA1 scaffolds, respectively). On gross inspection,
dense ECM deposits were apparent within devitalized lung tumors in KrasLA1
scaffolds, whereas KrasWT scaffolds had a homogeneous appearance (Fig. 1A).
Micro-computed tomographic imaging following airway inflation revealed that
KrasLA1 scaffolds had loss of the dimpled surface appearance of KrasWT scaffolds
(Fig. 2). There were numerous dense collagen bundles within devitalized lung
tumors as evidenced by Masson’s trichrome staining (Fig. 1B). Transmission
electron microscopic analysis demonstrated an increased proportion and thickness
of collagen bundles within devitalized lung tumors (Fig. 1C). In light of the collagen
enrichment of KrasLA1 scaffolds, we examined the stiffness of non-devitalized lung
tumors relative to that of normal lung tissues using a mechanical testing device that
measures the bulk compressive properties of tissue punches irrespective of sample
geometry. Tumors from KrasLA1 mice had greater stiffness than did normal lungs
from wild-type littermates (Fig. 1D).
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Figure 1. Collagen-rich tumor ECM. (A) ECM scaffolds were created by detergentbased de-cellularization of whole lungs isolated from Kras

LA1

mice and wild-type

mice. KrasWT scaffolds have a homogeneous appearance (A, left panel) whereas
Kras

LA1

scaffolds have areas of hyperdense stroma (arrow) in tumoral regions (A,

right panel). (B, C) Dense collagen bundles in tumoral regions of Kras

LA1

scaffolds

by Masson’s tri-chrome stain (B) and transmission electron microscopy (C, right
panel) were absent in KrasWT scaffolds (C, left panel). T, tumor; N, normal lung. (D)
Compressive moduli of punch biopsies from normal lung (n=13) and lung tumors
(n=9) were measured using a mechanical testing device. Scatter plot representation
of compressive modulus in each tissue sample (squares), mean values in each
cohort (long line), and standard deviations (short line). P-values are indicated (ttest).
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Figure 1

Figure 2. Micro-computed tomography images illustrate surface architecture of
scaffolds. Dimpled surface architecture of KrasWT scaffolds (top panel) is attenuated
LA1

in Kras

scaffolds (bottom panel).
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Figu
ure 2
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To

investigate

ECM

composition

of

the

devitalized

lungs,

liquid

chromatography-mass spectrometry (LC-MS/MS) analysis was performed on
scaffold protein extracts following reciprocal acrylamide labeling of cysteine
residues (schema diagrammatically illustrated in Fig. 3A). Quantification of spectra
from KrasWT and KrasLA1 scaffolds demonstrated up- or down-regulation of 211
proteins (> 1.5-fold, P < 0.05, same trend with reverse labeling, Table 2) that were
enriched in multiple Gene Ontology terms, including “carbohydrate catabolism”
(p=1.7E-06), “mitochondrion” (p=9.32E-06), and “glucose catabolism” (p=1.98E-04)
(Fig. 3B). KrasLA1 scaffolds were enriched in multiple ECM peptides, including
collagen type I α1 (2.03-fold), fibronectin (1.56-fold), SPARC (2.11-fold) and
tenascin X (2.36-fold) (Table 3). A number of cleaved forms of cathepsin family
members were up-regulated, including Ctha (2.17-fold), Cthb (2.22-fold), Cthc
(2.78-fold), Cthd (2.35-fold) and Cthh (6.56-fold), as were the membrane scaffolding
proteins Anxa1 (2.26-fold), Anxa3 (1.78-fold), and Anxa4 (2.61-fold) (Table 3).
Conversely, other ECM peptides were down-regulated in KrasLA1 scaffolds that
were enriched in the GO terms “extracellular region” (p=1.09E-07), “collagen type
IV” (p=6.94E-04), and “sheet-forming collagen” (p=6.94E-04) (Fig. 3C), including
collagen type IV isoforms α3, α4, and α5 (all > 1.6-fold decrease, Table 3). Thus,
lung tumorigenesis was accompanied by specific changes in ECM peptide content.
Given that lung tumors in KrasLA1 mice are infiltrated by a Thy-1pos population
of CAFs we examined next whether CAF matrices contribute to the desmoplastic
response observed in the lung scaffolds. Flow sorting was performed on the lungs
of syngeneic wild-type mice and KrasLA1 mice to isolate LFs and CAFs, respectively
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Figure 3. Strategy for global proteomic profiling of decellularized lung scaffolds. (A)
Experimental strategy for quantitative proteomic analysis of lung scaffolds. Cysteine
residues in tissues were labeled with heavy and light acrylamide and quantified
using liquid chromatography-mass spectrometry (LC-MS/MS). (B, C) Gene
Ontology (GO) classifications (Term) significantly enriched in proteins up-regulated
(B) or down-regulated (C) in KrasLA1 scaffolds. Classifications listed in rank order
based on p-values (modified Fisher exact test).
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Figu
ure 3
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Table 2. ECM-related peptides up- and down-regulated in Kras
analysis. LC-MS/MS analysis of Kras

WT

and Kras

LA1

LA1

scaffold profiling

scaffolds. Peptides listed are

limited to those with consistent changes (> 1.5-fold up-regulation and < -1.5-fold
down-regulation, p-values < 0.05, t-test) by reciprocal labeling. Normalized fold
change values greater than one indicate positive up-regulation (fold regulation =
fold change). Normalized fold change values less than one indicate down-regulation
(fold regulation = -1/fold change).
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WT

LA1

Table 2. LC-MS/MS analysis of K-ras and K-ras
(ECM-related peptides).

Gene

Fold regulation
LA1
WT
(Kras / Kras )
> 1.5 fold up-regulation, p < 0.05

scaffolds

p-value

Col1a1
Fn1
Bgn
Tnxb
Lamb1
Sparc
Actr3
Myh14
Myl6
Capzb
Des
Dstn
Tagln2
Ctsa
Ctsb
Ctsc
Ctsd
Ctsh
Anxa1
Anxa3

2.03
1.56
1.91
2.36
1.50
2.11
1.75
1.78
3.26
1.65
2.31
2.54
1.53
2.17
2.22
2.78
2.35
6.56
2.26
1.78

9.36E-07
4.81E-11
1.42E-14
8.66E-09
2.68E-03
5.62E-05
2.16E-04
1.06E-01
4.44E-11
1.42E-01
6.14E-04
7.77E-18
5.99E-06
3.81E-03
1.07E-03
1.89E-05
1.74E-17
4.62E-07
7.71E-07
2.65E-03

Anxa4

2.61

9.42E-290

< -1.5 fold down-regulation, p < 0.05
Col4a3
Col4a4
Col4a5
Crtap
Fgb
Fgg
Pcolce2

-1.61
-1.67
-1.80
-1.71
-1.54
-1.51
-1.62
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3.85E-05
1.92E-07
9.37E-08
1.20E-03
2.02E-22
1.42E-12
3.28E-06

Table 3. Functional classifications of ECM-related peptides up- and down-regulated
in Kras

LA1

scaffold profiling analysis. Cellular function-based grouping of peptides

identified in Table 2) which met cut-off threshold of > 1.5 fold up-regulation or < -1.5
down-regulation with a p < 0.05, (t-test).
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s of peptide
es identified
d in LC-MS//MS
WT
LA
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analysis of
o K-ras and K-ras scaffoldss.

33

(Fig. 4 illustrates schema for cell isolation and relative abundance of sorted cells).
We performed comparative mRNA expression profiling studies on CAFs and LFs by
using a quantitative reverse transcriptase PCR array that includes 84 ECM-related
genes. The only gene up-regulated more than 4-fold in CAFs was Col1a1 (15-fold)
(Fig. 5A), which was confirmed by immunostaining of LFs and CAFs with anticollagen type I antibodies (Fig. 6). Twelve matrix metalloproteinase (MMP) family
members were down-regulated in CAFs, including MMP-1, MMP-8, and MMP-13
(Fig. 5B), which have fibrillar collagenolytic activity (31). These findings support a
role for CAFs in intra-tumoral desmoplasia in KrasLA1 mice.
We posited that differences in matrix content play a critical role in tumor cell
adherence and invasion and tested this hypothesis by examining first the adherence
of non-metastatic (393P) and highly metastatic (344SQ) KP cell lines (22) to
collagen type I and other ECM molecules. Metastatic 344SQ cells were significantly
more adherent to collagen type I than non-metastatic 393P cells were, and neither
cell line adhered to collagen IV, laminin, or fibronectin at a higher affinity than they
did to BSA control (Fig. 5C). Next, we co-cultured LFs or CAFs with a KP cell line
(344SQ) that forms polarized spheres in 3-D Matrigel cultures (Fig. 7A). After
polarized sphere formation, the structures were overlaid with LFs or CAFs, which
revealed that the spheres acquired invasive properties in co-culture with CAFs but
not LFs (Fig. 7B). To determine whether CAF matrices are sufficient to mediate
tumor cell invasion, purified matrices isolated from CAF mono-cultures were
overlaid on polarized spheres. The spheres that were in direct contact with the CAF
matrix acquired invasive phenotypes, whereas spheres that were not in contact with
34

Figure 4. Prospective isolation strategy for LF and CAF stromal cell compartments.
Flow cytometric isolation of CD45NegCD31NegEp-CAMNegThy-1Pos fibroblasts from
digested lung tissues of wildtype mice (A) and KrasLA1 mice (B). Fluorochrome
labeled antibody intensity is illustrated on logarithmic scale. Cell populations are
labeled based on cell surface phenotype identification (hematopoietic, CD45Pos;
endothelial, CD31PosSca-1Pos; epithelial, Ep-CAMPos; and fibroblastic, Thy-1pos [red,
boxed]). Arrows indicate subgating of non-hematopoietic and non-endothelial cells
only. Relative frequencies of cell populations are indicated (left plots, % of total
viable cells; right plots, % of non-hematopoietic, non-endothelial subgates).
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Figure 4
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Figure 5. CAFs secrete abundant collagen type I and down-regulate collagenolytic
MMP family members. (A) Quantitative RT-PCR analysis of RNA samples from LFs
and CAFs using an ECM-specific microarray. Logarithmic scale scatter plot
displaying all genes on array as 2^-delta cycle threshold (Ct) values for CAFs (yaxis) and LFs (x-axis). Central line indicates unchanged gene expression. Cut-off
set at 4-fold up- or down-regulation (outer lines). Genes up-regulated > 4-fold (red);
down-regulated > 4-fold (green); or up-regulated < 4-fold or –down-regulated < 4fold (grey). All genes were normalized to GAPDH and -actin endogenous housekeeping genes. CT values >35 were considered non-detectable and are not
illustrated. (B) Bar graph illustration of down-regulated genes in (A). MMPs with and
without fibrillar collagenolytic activity are illustrated. Results expressed as foldchange in CAFs relative to LFs, which was set at 0. (C) Adherent cells were stained
with crystal violet and quantified colorimetrically 1 h after seeding on plastic or
coated with indicated ECM molecules or bovine serum albumin (BSA) as a control.
Results expressed as mean values (± S.D.) of triplicate wells. P-values are
indicated (t-test).
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Figure 6. CAF fibrillar collagen I secretion in vitro. Images of LFs (top panel) and
CAFs (bottom panel) grown in monolayer culture that were immunofluorescently
stained using an anti-collagen type I antibody (red). DAPI (blue).
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Figure 6
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Figure 7. CAFs induce tumor cell invasion through contact-dependent matrix
secretion. (A) Light microscopic image of metastatic 344SQ tumor cells seeded into
Matrigel and allowed to form polarized epithelial spheres. (B) Spheres were overlaid
with LFs (left panel) or CAFs (right panel). Spherical morphology was disrupted by
CAFs but not LFs. (C) Polarized spheres were overlaid with matrices extracted from
CAFs. Representative images of spheres that do not (left panel) or do (right panel)
have direct contact with matrices. Arrow (right panel) indicates invasive outgrowth.
Size bars are indicated.
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Figure 7
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matrix did not change (Fig. 7C). These findings support the conclusion that CAF
matrices promote tumor cell adherence and invasion.

Aberrant organization of basement membranes in tumor ECM
To examine ECM ultrastructural features, transmission electron microscopic
analysis was performed on wild-type and KrasLA1 scaffolds. Features unique to
KrasLA1 scaffolds included an abundance of amorphous material dispersed
throughout the matrix (Fig. 8A) and basement membranes that exhibited a loss of
lamina densa electron-dense bodies (Fig. 8B) and an increase in thickness (Fig.
8C) indicative of a loss of the normal, compact organization. Immunofluorescent
staining of lung tissues from KrasLA1 mice demonstrated that the basement
membrane component collagen IV was less abundant in tumor tissues than it was in
normal adjacent lung (Fig. 8D). One possible explanation for these findings is
reduced secretion of basement membrane proteins by CAFs, which we examined
by performing LC-MS/MS analysis on matrices purified from CAFs and LFs. A total
of 1,030 peptides were differentially expressed (G value >1.65, fold-change >1.5,
Table 4). Gene Ontology classifications for the top 100 up-regulated CAF peptides
demonstrated enrichment in “actin polymerization” (p=1.32E-03), “cytoskeletal
protein binding” (p=1.95E-05) and “cell cortex” (p=3.92E-04) (Fig. 9A), whereas
down-regulated peptides were enriched in “extracellular matrix” (p=7.39E-07) and
“calcium ion binding” (p=7.31E-05) (Fig. 9B). With respect to specific peptides that
were differentially expressed, CAF-derived matrices had increased abundance of
proteins that regulate cell motility, including spectrin protein Spna2 (2.42-fold) and
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Figure 8. Loss of basement membrane organization within tumor ECM. (A)
Ultrastructural features of KrasWT scaffolds (left panel) and KrasLA1 scaffolds (right
panel) demonstrating abundant collagen I fibers and amorphous material (arrow, right
panel) in KrasLA1 scaffolds. (B) Basement membranes in KrasWT scaffolds (left panel)
and KrasLA1 scaffolds (right panel). Collagen fibers in KrasWT scaffolds are compressed
and have lamina densa-associated electron-dense bodies (arrow). Basement
membranes in KrasLA1 scaffolds are less organized (right versus left panels) and lack
electron dense bodies. Size bars are indicated. (C) Diameters of basement membranes
in KrasWT and KrasLA1 scaffolds. Diameters represent mean values ± S.D. of replicates
(n=3 per genotype). (D) Reduced collagen type IV expression in tumors.
Representative immunofluorescent images of lung tumor and adjacent normal lung
tissues in KrasLA1 mice subjected to immunofluorescent staining with anti-collagen type
IV antibodies (green) and DAPI (blue). N, normal lung; T, tumor.
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Figure 9. Global proteomic profiling of enriched fibroblast matrices. Gene Ontology
(GO) classifications (Term) of top 100 up-regulated (A) or down-regulated (B)
peptides based on LC-MS/MS analysis of matrices extracted from LFs and CAFs in
mono-culture. Classifications listed in rank order based on p-values (modified Fisher
exact test).
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Figurre 9
47

Table 4. ECM-related peptides up- and down-regulated in CAF matrix profiling
analysis. LC-MS/MS analysis of normal and cancer-associated fibroblast matrices.
Peptides listed are limited to mouse origin only (removing bovine peptides derived
from FBS) with changes (> 1.5 fold up-regulation and < -1.5 down regulation, Gvalues >1.65, g-test). Normalized fold change values greater than one indicate
positive up-regulation (fold regulation = fold change). Normalized fold change
values less than one indicate down-regulation (fold regulation = -1/fold change). *
LA1

indicates peptides differentially expressed in Kras
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scaffolds (Table 2).

Table 4. LC-MS/MS analysis of LF and CAF matrices (ECM-related peptides).
Gene
Col1a2*
Col5a1
Col5a3
Tnxb*
Spna2
Ankar
Cdh23
Dstn*
Fblim1
Arhgef12
Arhgap17
Arhgap18
Ktn1
Ctse
Ctsh*
Ctsl
Anxa4*
Anxa11
Col6a1
Col6a2
Col6a3
Col9a2
Col18a1
Emilin1
Fgg*
Arhgef1
Arhgdia
Col4a2*
Hspg2
Nid1
Lama3
Lama5
Lamb1
Lamb2
Lamc1
Lamc2
Lbr

Fold regulation
(CAF / LF)
> 1.5 fold up-regulation g > 1.65
5.10
4.08
4.08
4.08
2.42
4.08
7.15
2.16
1.58
4.08
3.93
3.01
9.21
2.41
10.23
1.66
2.08
5.10
< -1.5 fold down-regulation, g > 1.65
-21.80
-17.00
-21.80
-5.00
-2.01
-4.20
-5.80
-4.20
-2.18
-1.99
-3.31
-13.00
-3.40
-10.60
-1.82
-2.25
-11.86
-3.40
-8.20
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g-value
3.77
2.50
2.50
2.50
8.02
2.50
6.54
33.54
2.11
2.50
6.07
4.48
9.50
2.54
11.03
12.20
17.85
3.77
29.25
21.54
29.25
3.64
1.77
2.65
4.69
2.65
4.56
2.56
23.34
15.25
1.73
11.59
3.08
3.79
41.21
1.73
8.04

destrin (2.16-fold), membrane scaffolding proteins (Anxa4 and Anxa11, 2.08- and
5.10-fold, respectively), and a protease (cathepsin H, 10.23-fold) reported to be
highly expressed in tumors from KrasLA1 mice (32) (Table 5). Conversely, several
basement membrane components were down-regulated, including collagen IV
(1.99-fold), which was also down-regulated in KrasLA1 scaffolds (Table 6), and
basement membrane-associated proteoglycans HSPG2 (3.31-fold) and nidogen-1
(13.00-fold) and laminin subunits Lama3 (3.40-fold), Lama5 (10.60-fold), Lamb1
(1.82-fold), Lamb2 (2.25-fold), Lamc1 (11.86-fold), and Lamc2 (3.40-fold) (Table 5).
Thus, the CAF secretome contained widespread changes in ECM content
(schematically illustrated in Fig. 10).

Multi-functional role of fibulin-2 during malignant progression
Given the above ultrastructural evidence that tumor ECM is highly
disorganized, we posited that matrix-stabilizing factors regulate malignant
progression (schematically illustrated in Fig. 11). Abundantly secreted by metastatic
KP cells, fibulin-2 is thought to stabilize the assembly of a variety of macromolecular
structures, including tropo-elastin fibers, microfibrils, and matrix-proteoglycan
complexes

and is required for cardiac tissue remodeling during myocardial

infarction, a hypoxic condition analogous to that observed in epithelial tumor ECM
(33). Western blot analysis of KP cell lines revealed that fibulin-2 was more
abundantly expressed in metastasis-prone (mesenchymal) KP cells than it was in
non-metastatic (epithelial) KP cells (Fig. 12A). Consistent with known splice
isoforms of fibulin-2, there were 2 bands of approximately 190 kD and 150 kD in
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Table 5. Functional classifications of ECM-related peptides up- and down-regulated
in CAF matrix profiling analysis. Cellular function-based grouping of peptides
identified in Table 4) which met cut-off threshold of > 1.5 fold up-regulation or < -1.5
down-regulation with a g-value >1.65, (g-test). * indicates peptides differentially
expressed in Kras

LA1

scaffolds (Table 2).
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Ta
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nd CAF ma
atrices.
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Table 6. Proteomic profiling comparison of in vivo scaffolds vs in vitro matrices
analysis. Comparison of peptides and corresponding functional classifications up
(+) and down (-) regulated within KrasLA1 tumor scaffolds and CAF matrices.
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Figure 10. Schematic illustration of CAF dependent effects on tumor-associated
ECM. CAF-derived collagen I is stabilized through down-regulation of collagenolytic
MMPs resulting in increased tumor desmoplastic scarring and CAF motility through
cytoskeletal elements. CAFs down-regulate basement membrane components and
up-regulate cathepsin h for increased tumor cell invasion. Collectively, CAFs
provide an intricate balance of ECM deposition,stabilization, down-regulation, and
degradation to provide an optimal microenvironment for tumor progression.
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Figure 11. Schematic illustration of proposed feed-forward model of tumor cellderived ECM stabilizing factors which regulate matrix stabilization. Unknown ECM
stabilizing factors interact with a mature, collagen-rich matrix derived primarily from
cancer-associated fibroblasts, which stimulates tumor cells to secrete additional
ECM molecules thereby engendering matrix stabilization.
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Figure 12. Fibulin-2 production in murine lung adenocarcinomas and normal tissue
specimens. (A) Western blot analysis of fibulin-2 expression in KP cell lines. Two
fibulin-2 species identified that differ on the basis of molecular weight (190 kD and
150 kD). β-actin included as loading control. (B) Densitometric analysis of western
blot in (A). Larger molecular weight band normalized on the basis of β-actin. (C)
Western blot analysis of fibulin-2 in CAFs and LFs. A single 190 kD band was
detected.

β-actin

included

as

loading

control.

(D-F)

Anti-fibulin-2

immunohistochemical staining (brown) of a lung adenocarcinoma from a KP mouse
(D), a nascent metastasis to lung in a syngeneic wild-type mouse injected
subcutaneously with 344SQ cells (E), and normal human lung adjacent to tumor (F).
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size, and the relative abundance of the larger band correlated with metastatic
propensity (Fig. 12B). Beyond its increase in metastasis-prone tumor cells, fibulin-2
was more abundantly expressed in CAFs than it was in LFs (Fig. 12C). Next, we
performed immunohistochemical studies on human and murine lung tissues to
examine fibulin-2 abundance and intra-tumoral localization. Fibulin-2 was detected
in primary lung tumors in KP mice (Fig. 12D) and in lung metastases from mice
injected subcutaneously with 344SQ cells (Fig. 12E). In human lung tissues, fibulin2 was detected in elastic tissues within bronchi and vascular structures adjacent to
tumor (Fig. 12F), in a “fibrillar” pattern between tumor cells and surrounding tumor
acini, and in a “fibrotic” pattern within intra-tumoral fibrotic bands (Fig. 13A). On the
basis

of

Kaplan-Meier

analysis

of

46

resected

primary

human

lung

adenocarcinomas, time-to-disease recurrence correlated negatively with “fibrotic”
fibulin-2 staining (Fig. 13B).
To test our hypothesis that matrix-stabilizing factors regulate malignant
progression, we inhibited fibulin-2 in metastasis-prone KP cells. Fibulin-2-deficient
KP cells were generated by stable transfection of one of six different shRNAs that
target distinct Fbln2 mRNA sequences. Two 344SQ transfectants (shFbln2 #1 and
#2) that achieved at least 50% knockdown relative to scrambled controls (shSCR)
(Fig. 14A-C) were injected subcutaneously or intra-thoracically into syngeneic wildtype mice to generate subcutaneous or intra-thoracic orthotopic tumors,
respectively. Relative to control shRNA-transfected tumors, fibulin-2-deficient
tumors were significantly smaller and generated fewer metastases regardless of
injection site (Fig. 15A-B). Confirmatory studies on a second KP cell line that has
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Figure 13. Fibulin-2 is highly expressed in human lung adenocarcinomas and
correlates with poor clinical outcome. (A) Anti-fibulin-2 immunohistochemical
staining

(brown)

of

two

different

primary

human

lung

adenocarcinomas

representative of fibrillar (top panel) and fibrous (bottom panel) staining patterns.
Size bars are indicated. (B) Surgically resected human lung adenocarcinomas
(n=46) fully annotated for demographic variables, pathologic stage, smoking status,
and clinical outcome were immunohistochemically stained using anti-fibulin-2
antibodies and quantitatively scored based on staining intensity and pattern.
Kaplan-Meier analysis (graph) of time-to-disease recurrence based on intensity of
fibrous fibulin-2 staining.
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Figure 14. Derivation of fibulin-2 shRNA knock down cells in a highly metastatic KP
cell line. (A) Quantitative RT-PCR assays on 344SQ cells stably transfected with
scrambled control shRNA (SCR shRNA) or Fbln2 shRNA #1 or #2. Values
normalized on the basis of L32 ribosomal RNA and expressed as the mean values
(± S.D.) of quadruplicate samples. Western blotting (B) and immunofluorescence
staining (C) of fibulin-2 in 344SQ cells stably transfected with control (SCR) or Fbln2
shRNA #1 or #2. Anti-fibulin-2 (red) and DAPI (blue).
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Figure 15. Fibulin-2 promotes the growth and metastatic properties of KP cells. (A)
Transfectants (106) injected into the flank of syngeneic wild-type mice (n=10 per
cohort) to generate subcutaneous tumors. Mice sacrificed after 6 weeks to weigh
primary tumor (top bar graph) and count visible lung metastases (bottom bar graph).
Scatter plot representation of each tissue sample (squares), mean values (long line)
and standard deviations (short line). P-values are indicated (t-test). (B) Syngeneic
mice (n=10 per cohort) were injected intra-thoracically with transfectants (2x104) to
generate a single orthotopic lung tumor. Mice were sacrificed after 2 weeks to
identify metastases to mediastinal lymph nodes and distant sites. Percentages of
mice in each cohort with metastases to mediastinal lymph nodes (bar graph). Pvalues are indicated (t-test).
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high fibulin-2 expression (531LN2) revealed that shRNA-mediated depletion of
fibulin-2 reduced the growth and metastasis of 531LN2 cells in syngenic mice (Fig.
16A-D). Furthermore, fibulin-2-deficient 344SQ cells exhibited reduced proliferation
in monolayer cultures (Fig. 17A), formed fewer colonies in soft agar (Fig. 17B and
Fig. 18A), and were less invasive in Boyden chamber assays (Fig. 17C and Fig.
18B). These profound changes in tumor cell biology justified investigations into
potential sequellae of fibulin-2 deficiency on tumor ECM content and structure.

Fibulin-2 stabilizes tumor ECM
Fibulin-2-deficient and –replete flank tumors were stained with Picosirius Red
to visualize collagen content. Quantification using Image J software revealed that
fibulin-2 deficiency reduced dense fibrous stroma deposition (Fig. 19A-C), which
resulted in a less compact ECM. Fibulin-2-deficient orthotopic lung tumors were
significantly less stiff than control tumors (Fig. 20A), and conditioned media samples
from fibulin-2-deficient cells were enriched in soluble (non-cross-linked) collagen
following pepsin digestion of exposed (uncross-linked) telopeptides (Fig. 20B). The
pronounced impact of fibulin-2 deficiency on collagen maturation was surprising
given that fibulin-2 does not colocalize to collagen type I fibers (34) and raised the
possibility that fibulin-2 deficiency changed the abundance of lysyl oxidase crosslinked enzymes. To this end fibulin-2 deficient cells had reduced LOXL-3 and -4
expression (Fig. 20C). We also explored whether fibulin-2 deficiency influenced
other ECM components required for matrix organization and remodeling. Indeed,
fibulin-2-deficient cells had reduced expression and secretion of many basement
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Figure 16. Fibulin-2 shRNA knock down in an additional metastatic KP cell line. (A)
Quantitative RT-PCR assays of 531LN2 cells stably transfected with Fbln2 shRNA
#3 and #4. Values normalized on the basis of L32 ribosomal RNA and expressed as
the mean values (± S.D.) of quadruplicate samples. (B) Western blotting of 531LN2
cells transfected with scrambled control shRNA (SCR shRNA) or Fbln2 shRNA #3
or #4. β-actin included as a loading control. (C, D) Transfectants (106) injected into
the flank of syngenic mice (n=10 per cohort) to generate subcutaneous tumors.
Mice sacrificed after 6 weeks to weigh primary tumors (C) and count lung
metastases (D). Scatter plot representation of each tissue sample (dots, squares,
triangles), mean values (long line), and standard deviations (short line). P-values
are indicated (t-test).
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Figure 17. Fibulin-2 regulates diverse biological properties of tumor cells in vitro.
(A) MTT assays to quantify relative cell density of transfectants grown in monolayer
cultures. Results expressed as mean values (± S.D.) at the indicated timepoints.
Asterisks indicate P < 0.01, SCR shRNA versus Fbln2 shRNA. (B) Colonies grown
in soft agar were counted after 21 days. Results expressed as mean values (± S.D.)
of each cohort (bar graph). (C) Transfectants loaded into upper chambers of
Boyden apparatus in the presence (+) or absence (-) of 10% serum in bottom
chamber as chemo-attractant. Cells invading through Matrigel-coated filter were
stained with crystal violet and quantified colorimetrically (triplicate samples). Results
expressed as fold-induction by serum (bar graph).
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Figure 17

Figure 18. Representative images from in vitro proliferation and invasion assays.
(A) Fibulin-2-deficient (shRNA #1 and #2) and –replete (SCR shRNA) 344SQ cells
were grown in soft agar for 21 days and photographed. (B) Fibulin-2-deficient (Fbln2
shRNA) and –replete (SCR shRNA) 344SQ cells were loaded into upper chambers
of Boyden apparatus in the presence (+) or absence (-) of 10% serum in bottom
chamber as chemo-attractant. Cells invading through Matrigel-coated filter were
stained with crystal violet and photographed.
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Figure 19. Fibulin-2-deficient tumors have a reduction in fibrous stroma resulting in
a less compact ECM. Picosirius Red (collagen) and hematoxylin (nuclei) stained
tumors (A) were converted into binary images using Image J software (B).
“Particles” defined as fully enclosed areas within the binary images were counted in
48 defined areas (grids) within the interior of the tumor, excluding subcutaneous
fascia, and the surface area of each particle was measured. Within a defined area,
stromal collagen density correlates directly with particle numbers and indirectly with
particle area. (C) Results were expressed as mean particle number per surface
area and mean particle area (bar graphs). P values (t-test) are indicated.
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Figure 20. Fibulin-2 regulates tensile properties, collagen solubility, basement
membrane expression, and MMP remodeling enzymes. (A) Compressive testing
performed on punch biopsies from un-injected lungs (n=13) and orthotopic lung
tumors from mice injected intra-thoracically with 344SQ cells stably transfected with
Fbln2 shRNA (n=9) or SCR shRNA (n=5). Results represent mean values ± S.D. of
triplicate samples. (B) Pepsin-soluble collagen (soluble) and total collagen (total) in
conditioned media samples were quantified by sircol assays and hydroxyproline
assays, respectively. Results represent mean values ± S.D. of triplicate samples.
(C,D) Quantitative RT-PCR values normalized on the basis of L32 ribosomal RNA
and expressed as the mean values (± S.D.) of quadruplicate samples relative to
SCR shRNA, which was set at 1.0. (E) MMP-2 and -9 zymography (gel) of
conditioned media samples from ex vivo lung perfusion model.

Densitometric

analysis of bands (bar graphs) in Fbln2 shRNA and SCR shRNA (n=3, each group).
Results represent mean values ± S.D. of triplicate samples. P-values are indicated
(t-test).
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membrane components including collagen IV and laminin (Fig. 21A-B) and reduced
mRNA expression of MMPs (Fig. 20D). To examine the role of lung tumor-derived
fibulin-2 in a native context, we used an ex vivo lung perfusion model in which
tissue scaffolds created by decellularization of rat lungs are injected with tumor cells
through the traches followed by continuous circulation of media through the
pulmonary artery under pump pressures and conditions that maintain lung tissue
architecture for up to 21 days (24). Fibulin-2-deficient or control 344SQ cells were
injected through the trachea and allowed to form parenchymal lung nodules over 3
days, at which point conditioned media samples were collected and subjected to
MMP zymography. Relative to scaffolds containing control tumor cells, scaffolds
containing fibulin-2-deficient cells had reduced MMP-2 and MMP-9 activities (Fig.
20E). Thus, fibulin-2 was essential for tumor cells to maintain production of intrinsic
matrix molecules and activated MMPs suggesting widespread effects on ECMrelated tumorigenic processes (schematically illustrated in Fig. 22).
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Figure 21. Fibulin-2-deficient cells have reduced secretion of basement membrane
components in vitro. (A) Quantitative RT-PCR values normalized on the basis of
L32 ribosomal RNA and expressed as the mean values (± S.D.) of quadruplicate
samples relative to SCR shRNA, which was set at 1.0. (B) 344SQ cells stably
transfected with Fbln2 shRNA or SCR shRNA were grown in monolayer culture and
immunofluorescently stained using either an anti-pan laminin or an anti-collagen IV
antibody (red). DAPI (blue).
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Figure 22. Schematic illustration of Fbln2-dependent effects on tumor-associated
ECM. Tumor cell-derived Fbln2 stimulates lysyl oxidase family member transcription
resulting in increased cross-linking of collagen for enhanced tumor stiffness. Fbln2
stimulates basement membrane secretion and ECM supramolecular assembly.
Fbln2 enhances gelatinase MMP production leading to selective degradation of
basement membrane components for increased tumor cell motility. Collectively,
Fbln2 provides an intricate balance of ECM deposition, degradation, and
stabilization to provide an optimal microenvironment for tumor progression and
metastasis.
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__________________________________________________________________
CHAPTER 4
__________________________________________________________________

DISCUSSION

Malignant progression of epithelial tumors is accompanied by a desmoplastic
reaction and other changes in tumor ECM composition and organization that create
regional heterogeneity and torsional stress (1). How tumors maintain ECM integrity
in the face of dynamic biophysical forces has not been fully elucidated. Here we
addressed this question in a mouse model of human lung adenocarcinoma marked
by disorganized basement membranes, dense collagen networks, and increased
tissue stiffness. We found that a matrix-stabilizing factor, fibulin-2, was abundant in
murine and human lung adenocarcinomas, and depletion of fibulin-2 from
metastasis-prone tumor cells disrupted the integrity of tumor ECM and inhibited
tumor growth and metastasis. On the basis of these findings, we propose a feedforward model in which tumor cells secrete matrix-stabilizing factors required for the
assembly of an ECM that favors malignant progression (schematically illustrated in
Fig. 23).
A proven oncogenic driver in epithelial cells of the lung, pancreas, and other
tissue types, mutant K-ras expression is associated with an intense tumor stromal
reaction (35). Moreover, fibrotic “scar” formation is a negative prognostic factor in
human lung adenocarcinomas (36). Although mutant K-ras is known to up-regulate
84

Figure 23. Schematic illustration of feed-forward model of tumor cell-derived fibulin2 dependent matrix stabilization. ECM stabilizing factor, Fbln2, stabilizes a mature,
collagen-rich matrix derived primarily from cancer-associated fibroblasts, which
stimulates tumor cells to secrete additional ECM molecules thereby engendering
matrix stabilization.
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the expression of chemokines and cytokines that function as chemoattractants for
stromal cells (35), whether CAFs contribute to mutant K-ras-driven desmoplasia has
not been elucidated. Here we showed that CAFs isolated from KrasLA1 mice
produce abundant collagen type I and are deficient in collagenolytic proteases,
supporting a role for CAFs in the desmoplasia associated with Kras-mutant tumors.
CAFs are heterogeneous and originate from multiple cell types, including
mesenchymal stem cells, smooth muscle cells, adipocytes, and native tissue
fibroblasts (37). Thy-1pos CAFs comprised less than 1% of tumor bulk in KrasLA1
mice, but the presence of other immunophenotypically distinct CAF populations in
these mice has not been excluded. Although their intra-tumoral location in KrasLA1
mice is unclear, CAFs are known to localize to areas of intra- and peri-tumoral
fibrosis where they perform contractile functions (38), a capacity supported by
evidence here that Thy-1pos CAFs have high expression of annexins and other
cytoskeletal motor proteins. In addition to promoting a desmoplastic reaction, CAFs
isolated from KrasLA1 mice secrete diverse cytokines and chemokines with the
potential to promote blood vessel growth, suppress anti-tumor immune responses,
and enhance tumor cell invasion (9). We showed that metastatic tumor cells
invaded in co-culture with CAFs and had increased adherence to collagen. Although
counter-intuitive to the prevailing belief that invasive capacity is associated with a
loss of adherence, increased adherence to collagen is consistent with evidence that
forced expression of collagen cross-linking enzymes LOR1 or LOXL2 in tumor cells
results in the formation of dense collagen fibers surrounding the tumors and the
development of invasive and metastatic disease (39, 40). Thus, CAF recruitment
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represents an important step in malignant progression and provides a selective
advantage to Kras-mutant tumor cells through the secretion of factors that play
multi-faceted roles in epithelial tumorigenesis (schematically illustrated in Fig. 10).
Expression profiling studies performed here revealed a complex protease
signature in CAFs that included down-regulation of collagenolytic MMPs and upregulation of multiple cathepsin family members (Ctsa, Ctsb, Ctsc, Ctsd, and Ctsh)
in CAFs. The murine cathepsin family of proteases includes 19 members that, in
epithelial tumors, originate from tumor cells and tumor-associated macrophages
and, as shown here, by CAFs (41, 42). In normal tissues, cathepsins participate in
intracellular turnover, immune response, and protein processing (42). In mouse
models of pancreatic cancer and breast cancer, cathepsin activity is pathogenic,
promoting tumor cell proliferation, angiogenesis, and apoptosis. Although mutant Kras drives the expression of certain cathepsin family members in tumor cells (43),
the latent KrasLA1 allele is in a germline configuration in CAFs isolated from KrasLA1
mice (9), arguing that mutant K-ras expression is not responsible for the increased
cathepsin expression in CAFs. Cathepsins are synthesized as inactive zymogens
that are activated by proteolytic removal of the N-terminal propeptide (42). LCMS/MS analysis of CAFs and LFs detected these cathepsins as cleaved forms,
implying that they were both over-expressed and activated. Cathepsins are involved
in direct proteolytic cleavage of basement membrane components such as laminins,
fibronectin, and type IV collagen (42), which, given the diminution of these ECM
molecules in KrasLA1 scaffolds, may underlie the aberrant organization of basement
membranes in KrasLA1 mice. The most prominently up-regulated cathepsin family
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member in KrasLA1 scaffolds was cathepsin H, which corroborates evidence that
cathepsin H is abundant in lung adenocarcinomas induced by activation of a
conditional KrasLA1 allele (32). In that study and a separate one on human lung
adenocarcinomas (44), cathepsin H was also detectable in normal lung adjacent to
lung tumors, which, given our findings, may reflect peri-tumoral localization of CAFs.
A growing body of evidence suggests that intrinsic matrix proteins may
function as drivers of tumorigenesis, which stands in contrast to their other role as a
barrier to tumor cell invasion (45). Several recent reports have shown that tenascin
C and periostin, which are matrix glycoproteins that form complexes with diverse
ECM proteins, including fibronectin, and are ligands for integrins and other
membrane receptors, play key roles as metastasis niche components for tumorinitiating cells (11, 46, 47). In breast tumors implanted orthotopically or arising
spontaneously owing to expression of polyoma virus middle T antigen, tenascin C
and periostin are expressed in tumor cells and CAFs in the metastatic niche and
enhance the survival and fitness of stem-like metastasis-initiating cells through
concentration of Wnt ligands

(11, 46, 47). Here we showed that a matrix

glycoprotein, fibulin-2, expressed in human lung adenocarcinomas and tumor cells
and CAFs derived from KrasLA1 mice is required for tumor growth and metastasis in
mice and predicts a worse outcome in patients with lung adenocarcinoma. Although
the impact of fibulin-2 on malignant progression in mice was clear, the prognostic
value of fibulin-2 in human lung adenocarcinomas may reflect the known prognostic
value of scar formation as opposed to a biological effect of fibulin-2 itself.
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In some respects, the functional similarities between fibulin-2, tenascin C,
and periostin are not surprising given that fibulin-2 forms complexes with tenascin
C, and the three proteins have overlapping binding partners in the ECM (17, 48).
However, several findings here suggest that fibulin-2 promotes tumorigenesis
through a distinct mechanism. Unlike tenascin C and periostin, fibulin-2 was not
required for lung colonization efficiency following tail vein injection, nor was it
required for properties of tumor cell stem-ness on the basis of polarized sphere
formation assays in 3-D cultures and expression of stem cell factors such as Nanog,
Oct4, or Sox2 (data not shown). Instead, fibulin-2 exerted a pro-tumorigenic effect
at the primary site, where it stabilized ECM organization and structure. Extending
the analogy of fibulin-2-deficient tumors to Fbln2-null mice subjected to myocardial
infarction (21), myocytes in damaged cardiac tissues and cells within the stroma of
epithelial tumors are both under chronic hypoxic stress and respond to tissue injury
by secreting intrinsic matrix proteins and matrix cross-linking enzymes (49, 50).
Findings presented here suggest that stress-induced matrix secretion is impaired in
fibulin-2-deficient tumors. The ECM of fibulin-2-depleted tumors was not only poorly
organized, a predicted phenotype of fibulin-2 deficiency on the basis of fibulin-2’s
capacity to form bridges between supra-molecular structures (20), but it was also
deficient in diverse intrinsic matrix proteins. Although this deficiency could be
related in part to rapid catabolism of damaged and poorly organized matrix proteins,
we showed that the expression of diverse ECM proteins is down-regulated in fibulin2-depleted tumor cells. On the basis of these findings, we propose a feed-forward
model in which epithelial carcinoma cells secrete fibulin-2, which leads to the
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assembly of a matrix with structure and organization that favors tumor growth and
metastasis.
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